StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report issued on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

NASDAQ GLMD opened at $3.56 on Friday. The firm’s fifty day moving average is $3.58 and its two-hundred day moving average is $4.07. Galmed Pharmaceuticals has a one year low of $2.73 and a one year high of $10.50. The firm has a market cap of $1.89 million, a PE ratio of -1.48 and a beta of 0.67.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.